ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market

Dec 19, 2022

American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their results for follicular lymphoma (FL).

The key abstracts have been summarized in the table below:

Drug regimen Downloads Article in PDF Recent Articles Abbvie-Genmab’s EPKINLY Approval for DLBCL Treatment: The First CD20XCD3 Bispecific Antibody Major Highlights of Follicular Lymphoma (FL) in ASH 2021 Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Ma... BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 ... Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!	Abstract Title	Trial ID	Company	Class	ORR	CR
Odronextamab	Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1â3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2	NCT03888105 (ELM-2)	Regeneron Pharmaceuticals	Bispecific antibody	81%	75%
Zandelisib¹ (ME-401)	Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study	NCT03768505 (TIDAL)	MEI Pharma	phosphatidylinositol 3-kinase (PI3K) delta inhibitor	85%	42%
Polatuzumab vedotin + Lenalidomide + Obinutuzumab	A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update	NCT02600897	Hoffmann-La Roche	Antibody Drug Conjugate	91%	72%
Mosunetuzumab²	Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study	NCT02500407 (GO29781)	Roche	Bispecific antibody	77.8%	60%
Iberdomide + Obinutuzumab³	Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study	NCT04464798	BMS	Immunomodulatory imide drug (IMiDs)	69%	39%

Notes:

1. MEI Pharma and Kyowa Kirin announced discontinuing Zandelisib development outside of Japan for B-cell malignancies. Moreover, Kyowa Kirin is continuing the ongoing clinical trials, including the Phase II MIRAGE study evaluating Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphomas and will explore the potential for submission to Japanese health authorities based on data from the MIRAGE and TIDAL clinical trials.

2. Lunsumio (mosunetuzumab) is already approved by European Commission in June 2022 for the treatment of people with R/R Follicular Lymphoma who have received at least two prior systemic therapies. Additionally, it was the first and only fixed-duration bi-specific antibody to be approved in Europe for lymphoma. Moreover, Lunsumio is under Priority Review with the FDA, with a decision expected by 29 December 2022.

3. Novel CELMoD (Cereblon E3 ligase modulators) is being evaluated for the treatment of R/R Follicular Lymphoma.